

ACTA PHARMACEUTICA

Croatian Pharmaceutical Society
10000 Zagreb, Masarykova 2/II, Croatia
Phone: +385 1 4872 849, fax: +385 1 4872 853
e-mail: hfd-fg-ap@zg.t-com.hr

Editor-in-Chief: Professor SVJETLANA LUTEROTTI, Ph. D.

E-mail: svjetlana.luterotti@pharma.hr
svjetlana.luterotti@gmail.com

Dear Author(s),

You are kindly asked to sign this agreement and forward it as an e-mail attachment, fax message or by post, along with submission of your manuscript to *Acta Pharmaceutica*, or upon request of the Editor. Please note that this is a prerequisite for any editorial/review processing and possible publication of your manuscript.

AUTHOR'S AGREEMENT FORM

1. Authorship/contributorship

Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. The order of authorships on the byline is a joint decision of all co-authors. Authors should be prepared to explain the order in which authors are listed. Authorship credits should be based on: (i) substantial contributions to the conception and design, or acquisition of data, or analysis and interpretation of data; (ii) drafting the article or revising it critically for important intellectual content; and (iii) final approval of the version to be published. Authors should meet all the three requirements.

All contributors that do not meet the criteria of authorship are mentioned in the acknowledgements.

2. Conflict of interest

Scientists have the ethical obligation to submit creditable research results. If the conditions of funding this research have the potential to bias or otherwise discredit the research, the authors must state explicitly whether potential conflicts do or do not exist. The Editor should be advised about any other conflict of interest.

3. Overlapping publications/authenticity

The authors warrant that the material submitted to *Acta Pharmaceutica* is original and has not been published and is not in press or under consideration for publication (except in the form of 1-page abstract or as part of academic thesis), whole or in part, in print or electronic format, in any other journal or any other medium, including preprints, electronic journals and computer databases in the public domain. This manuscript is being considered with the understanding it is submitted on an exclusive basis.

The author will alert the Editor if the manuscript includes subjects about which the authors have published in a previous report or have submitted a related report to another publication. Any such report must be referred to and referenced in the new paper.

The authors also warrant that the manuscript they are submitting to *Acta Pharmaceutica* is not plagiarized from any paper previously published by other scientists, or copied from their own.

4. Ethical standards

The authors certify that recommendations to comply with ethical standards when performing clinical and other biological experiments have been adhered to.

According to uniform requirements for manuscripts submitted to biomedical journals, when reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration and its revisions. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

5. Editorship/copyright

The authors submit their manuscript to AP on the understanding that it is subject to editorial review and peer review of at least two independent referees. In the case of contradicting reviews of two referees, the manuscript is sent to a third one and/or subjected to editorial evaluation. Editorial staff reserves the right to make editorial corrections to the manuscript and adjust it to the requirements of the journal. The authors grant to the AP the right to edit, revise, abridge and condense their manuscript and to make the final decision on the category of their paper.

In the case of the re-use of materials from copyrighted sources (*e.g.*, artwork) by the authors, proper proof of permission to re-use it, for print and electronic publication, must be supplied.

AP is an open access (OA) journal. In the case that the manuscript should be accepted for publication in AP (including hard form, electronic form or both) the authors hereby transfer the copyright of the paper to the journal's publisher, Croatian Pharmaceutical Society, Zagreb, Croatia. The authors permit AP to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given.

6. Publication charges

Publication charge is 450 € per manuscript (excl. VAT).

Authors will receive an invoice right after acceptance of their paper which will not be published before the fee has been paid. Prices are subject to change without notice.

Title of the paper _____

List of all authors and signatures _____

Corresponding author _____
Title _____
Institution _____
Place/date _____